CTOs on the Move

Rimsys Regulatory Management Software

www.rimsys.io

 
Learn about the first and only holistic Regulatory Information Management (RIM) software for medical device companies that consolidates all the functions of regulatory affairs.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.rimsys.io
  • 100, South Commons
    Pittsburgh, PA USA 15212
  • Phone: 855.846.7269

Executives

Name Title Contact Details
Jeff Burk
Chief Technology Officer Profile

Similar Companies

Galmed Pharmaceuticals

Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. Galmed Pharmaceuticals Galmed’s business has been, in its current legal structure, was incorporated in Israel on July 31, 2013 as a privately held company. However, operating since 2000 under a different group of companies established in the same year. Galmed was co-founded by Professor Tuvia Gilat and Allen Baharaff, based on Professor Gilat’s extensive research in FABAC’s and NASH.

Transtracheal Systems Inc

Transtracheal Systems Inc is a Englewood, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mobile Physician Services

Mobile Physician Services is a practice of doctors and nurse practitioners who make house calls to homebound patients. We specialize in the treatment of patients with complex medical needs. MPS is one of the only house call practices in the United Sta...

Olema

Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. At Olema we leverage the exquisite knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development.